Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Am J Surg ; 237: 115809, 2024 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-38945726

RESUMO

BACKGROUND: Secondary adrenal tumors (SATs) are uncommon, and the benefits of adrenalectomy for SATs have not been well-established. A systematic review and meta-analysis were conducted to assess the survival benefits of adrenalectomy for SATs. METHOD: ology: A systematic literature search was performed (1990-2022). The inclusion criteria included a known primary tumor with confirmed adrenal metastasis in patients who underwent adrenalectomy. The primary outcome was the overall survival (OS). RESULTS: A total of 26 studies were included, with 2279 patients. The average age at the time of diagnosis was 61.1 years. Lung cancer was the most common primary tumor. The average time from primary tumor diagnosis to identification of adrenal metastasis was 17 months. The median OS was 35.2 months. One, three, and five-year OS were 79.7 â€‹%, 49.1 â€‹%, and 37.9 â€‹%, respectively. CONCLUSION: The results of this review provide insight into the long-term survival of patients with SATs who underwent adrenalectomy. The study highlights the need for further research to identify the risk factors that play a role in the outcome of adrenalectomy in patients with SATs.


Assuntos
Neoplasias das Glândulas Suprarrenais , Adrenalectomia , Humanos , Neoplasias das Glândulas Suprarrenais/cirurgia , Neoplasias das Glândulas Suprarrenais/mortalidade , Neoplasias das Glândulas Suprarrenais/secundário , Taxa de Sobrevida
2.
JAMA Oncol ; 9(10): 1401-1416, 2023 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-37676656

RESUMO

Importance: Lip, oral, and pharyngeal cancers are important contributors to cancer burden worldwide, and a comprehensive evaluation of their burden globally, regionally, and nationally is crucial for effective policy planning. Objective: To analyze the total and risk-attributable burden of lip and oral cavity cancer (LOC) and other pharyngeal cancer (OPC) for 204 countries and territories and by Socio-demographic Index (SDI) using 2019 Global Burden of Diseases, Injuries, and Risk Factors (GBD) Study estimates. Evidence Review: The incidence, mortality, and disability-adjusted life years (DALYs) due to LOC and OPC from 1990 to 2019 were estimated using GBD 2019 methods. The GBD 2019 comparative risk assessment framework was used to estimate the proportion of deaths and DALYs for LOC and OPC attributable to smoking, tobacco, and alcohol consumption in 2019. Findings: In 2019, 370 000 (95% uncertainty interval [UI], 338 000-401 000) cases and 199 000 (95% UI, 181 000-217 000) deaths for LOC and 167 000 (95% UI, 153 000-180 000) cases and 114 000 (95% UI, 103 000-126 000) deaths for OPC were estimated to occur globally, contributing 5.5 million (95% UI, 5.0-6.0 million) and 3.2 million (95% UI, 2.9-3.6 million) DALYs, respectively. From 1990 to 2019, low-middle and low SDI regions consistently showed the highest age-standardized mortality rates due to LOC and OPC, while the high SDI strata exhibited age-standardized incidence rates decreasing for LOC and increasing for OPC. Globally in 2019, smoking had the greatest contribution to risk-attributable OPC deaths for both sexes (55.8% [95% UI, 49.2%-62.0%] of all OPC deaths in male individuals and 17.4% [95% UI, 13.8%-21.2%] of all OPC deaths in female individuals). Smoking and alcohol both contributed to substantial LOC deaths globally among male individuals (42.3% [95% UI, 35.2%-48.6%] and 40.2% [95% UI, 33.3%-46.8%] of all risk-attributable cancer deaths, respectively), while chewing tobacco contributed to the greatest attributable LOC deaths among female individuals (27.6% [95% UI, 21.5%-33.8%]), driven by high risk-attributable burden in South and Southeast Asia. Conclusions and Relevance: In this systematic analysis, disparities in LOC and OPC burden existed across the SDI spectrum, and a considerable percentage of burden was attributable to tobacco and alcohol use. These estimates can contribute to an understanding of the distribution and disparities in LOC and OPC burden globally and support cancer control planning efforts.


Assuntos
Carga Global da Doença , Neoplasias Faríngeas , Adulto , Feminino , Humanos , Masculino , Saúde Global , Incidência , Lábio , Neoplasias Faríngeas/epidemiologia , Anos de Vida Ajustados por Qualidade de Vida , Fatores de Risco , Uso de Tabaco/epidemiologia
3.
Curr Drug Metab ; 20(11): 924-928, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31702486

RESUMO

BACKGROUND: Metoclopramide is mainly metabolized by CYP2D6, CYP3A4, CYP2C19, and CYP1A2 enzymes, while cilostazol is also metabolized by CYP3A4, CYP2C19, and CYP1A2 enzymes. AIM: This study evaluates the effect of cilostazol on the pharmacokinetics of oral metoclopramide. METHODS: This was a randomized, two-phase cross-over pharmacokinetic study separated by a 4-week wash-out time period, 12 healthy non-smoking volunteers received metoclopramide 20 mg as a single oral dose and after 4 weeks, cilostazol 100 mg twice daily for 4 days then with metoclopramide 20 mg on test day. Serial blood samples were analyzed by using a validated high-performance liquid chromatography-ultraviolet method to determine maximum plasma drug concentration (Cmax), time to reach (Tmax), and area under the curve (AUC0-∞) of metoclopramide. RESULTS: Cilostazol increased the mean Cmax, AUC0-∞ and half-life (T1/2) of metoclopramide by 6%, 27% and by 0.79 %, respectively. In addition, Tmax of metoclopramide was delayed by cilostazol. CONCLUSION: The results showed delayed Tmax of metoclopramide by cilostazol, which could lead to the conclusion that cilostazol affects the absorption of metoclopramide. Both drugs when necessary to administer together must not be administered at the same time especially when given in gastroparesis patients.


Assuntos
Cilostazol/farmacocinética , Metoclopramida/farmacocinética , Administração Oral , Adulto , Cilostazol/farmacologia , Estudos Cross-Over , Interações Medicamentosas , Humanos , Masculino , Metoclopramida/farmacologia
5.
Curr Radiopharm ; 5(1): 34-7, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-21864247

RESUMO

Inactivation constant for V79 cells has been extracted from radiobiology experiments that utilize charged particles to irradiate mammal cells in vitro. Physical parameters such as effective charge, radiation mean free path and linear ionization which characterized protons and heluim-4 particles are determined using of standard values. The relationship between inactivation constant α and physical quality parameters have been determined, in this research, for protons and heluim-4 particles. This approach allows getting the characteristic biological response of inactivation of V79 cells in terms of each selected physical quality parameter. The best regression models are formulated for each obtained relationship.


Assuntos
Hélio , Transferência Linear de Energia , Prótons , Radiação Ionizante , Animais , Células Cultivadas , Relação Dose-Resposta à Radiação , Mamíferos , Doses de Radiação , Eficiência Biológica Relativa , Eletricidade Estática
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA